Investigating factors affecting survival rates in African American women with ER+ breast cancer
SQLE and Sterols Contribute to Racial Disparity in ER+ Breast Cancer Patient Survival
This study is looking into why African American women with a specific type of breast cancer tend to have lower survival rates than white women, focusing on a particular enzyme that might be causing this issue, with the goal of finding better treatment options just for them.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-10758961 on NIH RePORTER |
What this research studies
This research focuses on understanding why African American women with estrogen receptor positive (ER+) breast cancer have worse survival rates compared to their white counterparts. The study aims to identify biological mechanisms, particularly the role of the enzyme SQLE, that may contribute to this disparity. By analyzing tumor samples and patient data, the researchers hope to uncover why these patients experience resistance to standard endocrine therapies. The findings could lead to improved treatment strategies tailored for African American women facing ER+ breast cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are African American women diagnosed with estrogen receptor positive breast cancer.
Not a fit: Patients with other types of breast cancer or those who are not African American may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments and improved survival rates for African American women with ER+ breast cancer.
How similar studies have performed: Previous research has indicated that biological factors contribute to disparities in cancer outcomes, suggesting that this approach may yield valuable insights.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Coloff, Jonathan L. — University of Illinois at Chicago
- Study coordinator: Coloff, Jonathan L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.